present dabigatran may be suitable for patients with high
stroke and bleeding risks such as frail older people with
multiple comorbidities and polypharmacy in whom anticoa-
gulation control is erratic or monitoring is not feasible.
Until the price of dabigatran is reviewed, warfarin remains
suitable for the majority of patients with NV AF.
• Cost of anticoagulation is largely driven by drug price for
dabigatran and quality of INR control for warfarin.
• Cost of dabigatran to prevent one stroke per year is about
four to five times that of warfarin.
• Majority of patients on warfarin therapy are not troubled
by frequent blood testing.
1. Singer DE, Albers GW, Dalen JE et al.. Antithrombotic
therapy in atrial fibrillation: the seventh ACCP Conference on
antithrombotic and thrombolytic therapy. Chest 2004; 126
2. Wang TJ, Massaro JM, Levy D et al.. A risk score for predict-
ing stroke or death in individuals with new onset atrial fibrilla-
tion in the community: the Framingham Heart Study. JAMA
2003; 290: 1049–56.
3. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombo-
tic therapy to prevent stroke in patients who have nonvalvular
atrial fibrillation. Ann Intern Med 2007; 146: 857–67.
4. Boulanger L, Kim J. Patterns of use of antithrombotic therapy
and quality of anticoagulation among patients with non-
valvular atrial fibrillation in clinical practice. Int J Clin Pract
2006; 60: 258–64.
5. Connnolly SJ, Ezekowitz MD, Yusuf S et al.. The RE-LY
Steering Committee and Investigators: dabigatran versus warfarin
in patients with atrial fibrillation. N Engl J Med 2009; 361:
6. Shah SV, Gage BF. Cost effectiveness of dabigatran for stroke
prophylaxis in atrial fibrillation. Circulation 2011; 123:
7. Abdelhafiz AH, Wheeldon NM. Use of resources and cost
implications of stroke prophylaxis with warfarin for patients
with nonvalvular atrial fibrillation. Am J Geriatr Pharmacother
2003; l: 53–60.
8. O’Donoghue J, Goulding L, Allen G. Consumer price infla-
tion since 1750. Eco Tren 2004; 604: 38–46.
9. National Institute for Health and Clinical Excellence. Final ap-
praisal determination-dabigatran etexilate for the prevention of
stroke and systemic embolism in atrial fibrillation. Issue date:
10. Freeman JV, Zhu RP, Owens DK et al.. Cost-effectiveness of
dabigatran compared with warfarin for stroke prevention in
atrial fibrillation. Ann Intern Med 2011; 154: 1–11.
11. Wallentin L, Yusuf S, Ezekowitz MD et al.. RE-LY investiga-
tors. Efficacy and safety of dabigatran compared with war-
farin at different levels of international normalized ratio
control for stroke prevention in atrial fibrillation: an analysis
of the RE-LY trial. Lancet 2010; 376: 975–83.
12. Gage BF, Waterman AD, Shannon W et al.. Validation of clin-
ical classification schemes for predicting stroke: results from
the National Registry of Atrial Fibrillation. JAMA 2001; 285:
Received 27 September 2011; accepted in revised form
4 January 2012
Age and Ageing 2012; 41: 684–689
Published electronically 19 April 2012
© The Author 2012. Published by Oxford University Press on behalf of the British Geriatrics Society.
All rights reserved. For Permissions, please email: firstname.lastname@example.org
The frailty index in Europeans: association with
age and mortality
ROMAN ROMERO-ORTUNO, ROSE ANNE KENNY
Department of Medical Gerontology, Trinity College Dublin, Dublin, Ireland
Address correspondence to: R. Romero-Ortuno. Tel: (+353) 1 428 4527; Fax: (+353) 1 410 3454. E-mail: email@example.com
Background: the frailty index (FI) is an approach to the operationalisation of frailty based on accumulation of deficits.
It has been less studied in Europeans.
Objective: to construct sex-specific FIs from a large sample of Europeans and study their associations with age and
R. Romero-Ortuno and R. A. Kenny
by guest on October 20, 2015
the 6th framework programme (projects SHARE-I3,
RII-CT-2006-062193, COMPARE, CIT5-CT-2005-028857
and SHARELIFE, CIT4-CT-2006-028812) and through the
7th framework programme (SHARE-PREP, 211909 and
SHARE-LEAP, 227822). Additional funding from the U.S.
National Institute on Aging (U01 AG09740-13S2, P01
AG005842, P01 AG08291, P30 AG12815, Y1-AG-4553-01
and OGHA 04-064, IAG BSR06-11, R21 AG025169) as
well as from various national sources is gratefully acknowl-
edged (see www.share-project.org for a full list of funding
Supplementary data mentioned in the text is available to
subscribers in Age and Ageing online.
1. Fedarko NS. The biology of aging and frailty. Clin Geriatr
Med 2011; 27: 27–37.
2. Fulop T, Larbi A, Witkowski JM et al. Aging, frailty and
age-related diseases. Biogerontology 2010; 11: 547–63.
3. Wick JY. Understanding frailty in the geriatric population.
Consult Pharm 2011; 26: 634–45.
4. Schuurmans H, Steverink N, Lindenberg S, Frieswijk N, Slaets
JP. Old or frail: what tells us more? J Gerontol A Biol Sci
Med Sci 2004; 59: M962–5.
5. Rockwood K, Mitnitski A. Frailty defined by deficit accumula-
tion and geriatric medicine defined by frailty. Clin Geriatr Med
2011; 27: 17–26.
6. Rockwood K, Mitnitski A. Frailty in relation to the accumula-
tion of deficits. J Gerontol A Biol Sci Med Sci 2007; 62:
7. Kulminski A, Yashin A, Arbeev K et al. Cumulative index of
health disorders as an indicator of aging-associated processes
in the elderly: results from analyses of the National Long
Term Care Survey. Mech Ageing Dev 2007; 128: 250–8.
8. Mitnitski AB, Graham JE, Mogilner AJ, Rockwood K. Frailty,
fitness and late-life mortality in relation to chronological and
biological age. BMC Geriatr 2002; 2: 1.
9. Kulminski A, Yashin A, Ukraintseva S et al. Accumulation of
health disorders as a systemic measure of aging: findings from
the NLTCS data. Mech Ageing Dev 2006; 127: 840–8.
10. Kulminski AM, Ukraintseva SV, Akushevich IV, Arbeev KG,
Yashin AI. Cumulative index of health deficiencies as a char-
acteristic of long life. J Am Geriatr Soc 2007; 55: 935–40.
11. Mitnitski AB, Mogilner AJ, MacKnight C, Rockwood K. The
mortality rate as a function of accumulated deficits in a frailty
index. Mech Ageing Dev 2002; 123: 1457–60.
12. Searle SD, Mitnitski A, Gahbauer EA, Gill TM, Rockwood
K. A standard procedure for creating a frailty index. BMC
Geriatr 2008; 8: 24.
13. Song X, Mitnitski A, Rockwood K. Prevalence and 10-year
outcomes of frailty in older adults in relation to deficit accu-
mulation. J Am Geriatr Soc 2010; 58: 681–7.
14. Xue QL, Walston JD, Fried LP, Beamer BA. Prediction of
risk of falling, physical disability, and frailty by rate of decline
in grip strength: the women’s health and aging study. Arch
Intern Med 2011; 171: 1119–21.
15. Syddall H, Cooper C, Martin F, Briggs R, Aihie Sayer A. Is
grip strength a useful single marker of frailty? Age Ageing
2003; 32: 650–6.
16. Romero-Ortuno R, O’Shea D, Kenny RA. The SHARE
frailty instrument for primary care predicts incident disability
in a European population-based sample. Qual Prim Care
2011; 19: 301–9.
17. Santos-Eggimann B, Cuenoud P, Spagnoli J, Junod J.
Prevalence of frailty in middle-aged and older community-
dwelling Europeans living in 10 countries. J Gerontol A Biol
Sci Med Sci 2009; 64: 675–81.
18. Finkelstein M. On the ‘rate of aging’ in heterogeneous popu-
lations. Math Biosci 2011; 232: 20–3.
19. Mitnitski AB, Mogilner AJ, MacKnight C, Rockwood K. The
accumulation of deficits with age and possible invariants of
aging. ScientificWorldJournal 2002; 2: 1816–22.
20. Golubev AG. The issue of feasibility of a general theory of
aging I. Generalized Gompertz-Makeham Law. Adv Gerontol
2009; 22: 60–73.
21. Rockwood K, Mogilner A, Mitnitski A. Changes with age in
the distribution of a frailty index. Mech Ageing Dev 2004;
22. Kulminski A, Ukraintseva SV , Akushevich I, Arbeev KG, Land
KYashin AI. Accelerated accumulation of health deficits as a
characteristic of aging. Exp Gerontol 2007; 42: 963–70.
23. Yang Y, Lee LC. Dynamics and heterogeneity in the process of
human frailty and aging: evidence from the U.S. older adult
population. J Gerontol B Psychol Sci Soc Sci 2010; 65B: 246–55.
24. Rockwood K, Song X, Mitnitski A. Changes in relative fitness
and frailty across the adult lifespan: evidence from the Canadian
National Population Health Survey. CMAJ 2011; 183: E487–94.
25. Gu D, Dupre ME, Sautter J, Zhu H, Liu Y, Yi Z. Frailty and
mortality among Chinese at advanced ages. J Gerontol B
Psychol Sci Soc Sci 2009; 64: 279–89.
Gutierrez-Robledo LM. A frailty index to predict the mortal-
ity risk in a population of senior Mexican adults. BMC
Geriatr 2009; 9: 47.
27. Berges IM,Graham JE,
Ottenbacher KJ. Sex differences in mortality among older
frail Mexican Americans. J Womens Health (Larchmt) 2009;
28. Goggins WB, Woo J, Sham A, Ho SC. Frailty index as a
measure of biological age in a Chinese population. J
Gerontol A Biol Sci Med Sci 2005; 60: 1046–51.
29. Shi J, Song X, Yu P et al. Analysis of frailty and survival
from late middle age in the Beijing Longitudinal Study of
Aging. BMC Geriatr 2011; 11: 17.
30. Hubbard RE, Rockwood K. Frailty in older women.
Maturitas 2011; 69: 203–7.
Ostir GV,Markides KS,
Received 27 November 2011; accepted in revised form
14 March 2012
The frailty index in Europeans
by guest on October 20, 2015